Bronchopulmonary Dysplasia Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Bronchopulmonary Dysplasia Therapeutics | DelveInsight

DelveInsight's Bronchopulmonary Dysplasia Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Bronchopulmonary Dysplasia therapies in various stages of clinical development. The report provides insights into 10+ companies and 12+ pipeline drugs in the Bronchopulmonary Dysplasia pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Bronchopulmonary Dysplasia Clinical Trial Landscape Report

• DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a developing space with 10+ companies working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
• Key Bronchopulmonary Dysplasia companies such as Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics, Inc., and others.
• Promising Bronchopulmonary Dysplasia pipeline therapies in various stages of development include Pneumostem, OHB-607, Endotracheopulmonary instillation, AT-100, and others.

Request a sample and discover the recent advances in Bronchopulmonary Dysplasia treatment drugs https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Bronchopulmonary Dysplasia?

Bronchopulmonary dysplasia (BPD) is a serious lung condition primarily affecting premature infants, particularly those born before 32 weeks of gestation or with low birth weight. It is characterized by abnormal lung development and inflammation, often resulting from prolonged oxygen therapy or mechanical ventilation required to support immature lungs.
Infants with BPD may experience difficulty breathing and may require long-term respiratory support. Common symptoms include rapid or labored breathing, persistent need for supplemental oxygen, wheezing, difficulty feeding, poor growth, and episodes of cyanosis. In severe cases, infants may develop chronic lung disease, frequent respiratory infections, and prolonged dependence on respiratory support.
BPD is typically diagnosed in premature infants who continue to require oxygen therapy or respiratory support after 28 days of life, particularly those born before 32 weeks of gestation. Diagnosis is based on clinical criteria, including oxygen dependence and radiographic evidence of lung abnormalities. Severity is also assessed based on the need for supplemental oxygen at 36 weeks postmenstrual age.
Treatment focuses on managing symptoms and supporting lung development. Key approaches include oxygen therapy or mechanical ventilation, diuretics, corticosteroids, nutritional support, and bronchodilators.

Emerging Bronchopulmonary Dysplasia Drug Profiles

Zelpultide alfa (AT-100): Airway Therapeutics, Inc.
Zelpultide alfa, also known as AT-100, is a novel biologic developed by Airway Therapeutics, Inc. It is a recombinant version of human surfactant protein D (rhSP-D), engineered to reduce inflammation and infection while modulating the immune response. The therapeutic candidate primarily targets Bronchopulmonary Dysplasia. Currently, the drug is in the Phase II/III stage of development for the treatment of Bronchopulmonary Dysplasia.

OHB-607: Oak Hill Bio
OHB-607, previously known as TAK-607, is a novel therapeutic candidate developed by Oak Hill Bio for extremely premature infants. It is a recombinant version of insulin-like growth factor 1 (IGF-1), combined with its binding protein IGFBP-3. The therapy is designed to prevent Bronchopulmonary Dysplasia by restoring IGF-1 levels to those typically present during full-term pregnancy and supporting the normal growth and development of vital organs such as the lungs, brain, and eyes. Currently, the drug is in the Phase II stage of development for the treatment of Bronchopulmonary Dysplasia.

Pneumostem: Medipost Co., Ltd.
Pneumostem is an emerging cell-based therapeutic included in DelveInsight's Bronchopulmonary Dysplasia pipeline landscape. It is being investigated as a potential treatment approach for premature infants affected by Bronchopulmonary Dysplasia and is among the key products covered in the report.

Learn more about the novel and emerging Bronchopulmonary Dysplasia pipeline therapies https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Bronchopulmonary Dysplasia Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Bronchopulmonary Dysplasia Companies: Medipost Co., Ltd., Oak Hill Bio, EXO Biologics S.A., Airway Therapeutics, Inc.
• Key Bronchopulmonary Dysplasia Pipeline Therapies: Pneumostem, OHB-607, Endotracheopulmonary instillation, AT-100

Dive deep into rich insights for new drugs for Bronchopulmonary Dysplasia treatment, visit https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Bronchopulmonary Dysplasia Pipeline Report Introduction
2. Bronchopulmonary Dysplasia Pipeline Report Executive Summary
3. Bronchopulmonary Dysplasia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Bronchopulmonary Dysplasia Pipeline Therapeutics
6. Bronchopulmonary Dysplasia Pipeline: Late Stage Products (Phase III)
7. Bronchopulmonary Dysplasia Pipeline: Mid Stage Products (Phase II)
8. Bronchopulmonary Dysplasia Pipeline: Early Stage Products (Phase I)
9. Bronchopulmonary Dysplasia Pipeline: Preclinical and Discovery Stage Products
10. Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment
11. Inactive Products in the Bronchopulmonary Dysplasia Pipeline
12. Key Companies
13. Key Products in the Bronchopulmonary Dysplasia Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Bronchopulmonary Dysplasia pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.